Cargando…

First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005–2015)

Children aged <2 years with chronic lung disease (CLD) have a 10-fold higher risk for respiratory syncytial virus-positive hospitalization (RSVH) compared to healthy term infants. Based on the updated position statements, we compared respiratory-related illness hospitalization (RIH) and RSVH risk...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Daniel Y., Li, Abby, Paes, Bosco, Mitchell, Ian, Lanctôt, Krista L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321716/ https://www.ncbi.nlm.nih.gov/pubmed/28105526 http://dx.doi.org/10.1007/s00431-017-2849-4

Ejemplares similares

Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005–2017
por: Kim, Doyoung, et al.
Publicado: (2019)

Respiratory-Related Hospitalizations following Prophylaxis in the Canadian Registry for Palivizumab (2005–2012) Compared to Other International Registries
por: Paes, Bosco, et al.
Publicado: (2013)

Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada
por: Mitchell, Ian, et al.
Publicado: (2021)

Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention
por: Chen, Jinghan Jenny, et al.
Publicado: (2015)

Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations
por: Paes, B., et al.
Publicado: (2011)

Erratum to: Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations
por: Paes, B., et al.
Publicado: (2012)

A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS)
por: Paes, B., et al.
Publicado: (2012)

Comparison of the Canadian vs. the international risk scoring tool for respiratory syncytial virus prophylaxis in moderate-to-late preterm infants
por: Butt, Michelle, et al.
Publicado: (2023)

Cost-analysis of Withdrawing Immunoprophylaxis for Respiratory Syncytial Virus in Infants Born at 33–35 Weeks Gestational Age in Quebec: A Multicenter Retrospective Study
por: Papenburg, Jesse, et al.
Publicado: (2020)

Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value
por: Olchanski, Natalia, et al.
Publicado: (2018)

Respiratory syncytial virus and palivizumab prophylaxis in the COVID-19 era
por: Taylor, Richard S.
Publicado: (2021)

Outcomes of Palivizumab Prophylaxis for Respiratory Syncytial Virus Infection in Preterm Children with Bronchopulmonary Dysplasia at a Single Hospital in Korea from 2005 to 2009
por: Chang, Seung Gu, et al.
Publicado: (2010)

The Burden and Long-term Respiratory Morbidity Associated with Respiratory Syncytial Virus Infection in Early Childhood
por: Fauroux, Brigitte, et al.
Publicado: (2017)

Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Infants with Chronic Lung Disease
por: Paes, Bosco, et al.
Publicado: (2016)

A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29–35 weeks’ gestational age
por: Keary, Ian P., et al.
Publicado: (2023)

Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)
por: Bollani, Lina, et al.
Publicado: (2015)

Assessment and optimization of respiratory syncytial virus prophylaxis in Connecticut, 1996–2013
por: Artin, Ben, et al.
Publicado: (2021)

Immune Prophylaxis Targeting the Respiratory Syncytial Virus (RSV) G Protein
por: Bergeron, Harrison C., et al.
Publicado: (2023)

Respiratory syncytial virus prophylaxis for prevention of recurrent childhood wheeze and asthma: a systematic review
por: Quinn, Lauren Alexandra, et al.
Publicado: (2020)

Respiratory Syncytial Virus Seasonality, Beijing, China, 2007–2015
por: Yu, Jianxing, et al.
Publicado: (2019)

Burden of Severe Respiratory Syncytial Virus Disease Among 33–35 Weeks’ Gestational Age Infants Born During Multiple Respiratory Syncytial Virus Seasons
por: Anderson, Evan J., et al.
Publicado: (2017)

Burden of Respiratory Syncytial Virus Hospitalizations in Canada
por: Mitchell, Ian, et al.
Publicado: (2017)

Health care costs of hospitalization of young children for respiratory syncytial virus infections: a population-based matched cohort study
por: Thampi, Nisha, et al.
Publicado: (2021)

Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
por: Mejías, Asunción, et al.
Publicado: (2008)

Rationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virus
por: Makari, Doris, et al.
Publicado: (2014)

Respiratory Syncytial Virus Infection in High-risk Infants – an Update on Palivizumab Prophylaxis
por: Resch, Bernhard
Publicado: (2014)

Utilization Management Opportunities for Palivizumab for Prophylaxis of Respiratory Syncytial Virus Complications in Infants
por: Curtiss, Frederic R., et al.
Publicado: (2010)

Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children
por: Simões, Eric A. F., et al.
Publicado: (2018)

Molecular Evolution of Respiratory Syncytial Virus Fusion Gene, Canada, 2006–2010
por: Papenburg, Jesse, et al.
Publicado: (2012)

Review of the home care programmes for respiratory syncytial virus (RSV) prophylaxis in Ireland and The Netherlands
por: Whelan, Barbara, et al.
Publicado: (2016)

Risk scoring tool to predict respiratory syncytial virus hospitalisation in premature infants
por: Blanken, Maarten O., et al.
Publicado: (2018)

Risk of Respiratory Syncytial Virus Hospitalization in the First and Second Years of Life in Pediatric Patients with Congenital Heart Disease
por: Friedman, Deborah, et al.
Publicado: (2017)

Defining the Epidemiology and Burden of Severe Respiratory Syncytial Virus Infection Among Infants and Children in Western Countries
por: Bont, Louis, et al.
Publicado: (2016)

Defining the Risk and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Preterm Infants Without Chronic Lung Disease or Congenital Heart Disease
por: Figueras-Aloy, Josep, et al.
Publicado: (2016)

Comparative global epidemiology of influenza, respiratory syncytial and parainfluenza viruses, 2010–2015
por: Lam, Tommy T, et al.
Publicado: (2019)

Burden and severity of children's hospitalizations by respiratory syncytial virus in Portugal, 2015–2018
por: Bandeira, Teresa, et al.
Publicado: (2022)

Respiratory syncytial virus‐associated deaths in the United States according to death certificate data, 2005 to 2016
por: Prill, Mila M., et al.
Publicado: (2021)

Defining the Incidence and Associated Morbidity and Mortality of Severe Respiratory Syncytial Virus Infection Among Children with Chronic Diseases
por: Manzoni, Paolo, et al.
Publicado: (2017)

A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom
por: Bentley, Anthony, et al.
Publicado: (2013)

Retrospective Multicenter Study of Respiratory Syncytial Virus Prophylaxis in Korean Children with Congenital Heart Diseases
por: Kim, Ah Young, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_f1gfdnsa6qr1h8nc4nhdoifl0f